|
|
|
Insider
Information: |
Goeddel David V |
Relationship: |
10% Owner |
City: |
So. San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
21,008,913 |
|
Indirect Shares
|
32,725,451 |
|
|
Direct
Value |
$111,094,577 |
|
|
Indirect Value
|
$153,393,180 |
|
|
Total
Shares |
53,734,364 |
|
|
Total
Value |
$264,487,757 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
63
|
4
|
Stock
price went up :
|
24
|
1
|
Stock
price went down : |
39
|
3
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-0.2%
|
-73.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
3,961,942 |
2014-07-29 |
0 |
Premium* |
|
Gritstone Oncology, Inc. |
GRTS |
Managing Partner |
2018-10-02 |
3,102,934 |
2018-10-02 |
0 |
Premium* |
|
Ngm Biopharmaceuticals Inc |
NGM |
Director, 10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
Rapt Therapeutics, Inc. |
RAPT |
Managing Partner, 10% ... |
2020-09-22 |
5,630,497 |
2019-11-04 |
195,401 |
Premium* |
|
Oric Pharmaceuticals, Inc. |
ORIC |
Managing Partner, 10% ... |
2020-04-28 |
4,768,181 |
|
0 |
Premium* |
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2020-11-16 |
2,151,026 |
2020-11-16 |
3,799,202 |
Premium* |
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
Tenaya Therapeutics, Inc. |
TNYA |
|
2021-08-03 |
0 |
2024-02-12 |
22,999,565 |
Premium* |
|
Effector Therapeutics Ord Shs |
EFTR |
10% Owner |
|
0 |
2021-08-25 |
4,309,329 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
145 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-06-21 |
4 |
B |
$14.03 |
$52,789 |
I/I |
3,763 |
15,871,851 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-06-24 |
4 |
B |
$13.78 |
$168,650 |
I/I |
12,240 |
15,884,091 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-11 |
4 |
B |
$13.87 |
$150,752 |
I/I |
10,870 |
15,894,961 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-12 |
4 |
B |
$13.88 |
$291,765 |
I/I |
21,014 |
15,915,975 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-15 |
4 |
B |
$13.69 |
$221,547 |
I/I |
16,188 |
15,932,163 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-16 |
4 |
B |
$13.86 |
$54,055 |
I/I |
3,900 |
15,936,063 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-19 |
4 |
B |
$13.99 |
$87,043 |
I/I |
6,222 |
15,942,285 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-22 |
4 |
B |
$13.54 |
$416,337 |
I/I |
30,760 |
15,973,045 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-23 |
4 |
B |
$13.35 |
$410,535 |
I/I |
30,760 |
16,003,805 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-24 |
4 |
B |
$13.51 |
$392,502 |
I/I |
29,054 |
16,032,859 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-25 |
4 |
B |
$13.37 |
$411,294 |
I/I |
30,753 |
16,063,612 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-26 |
4 |
B |
$13.59 |
$408,634 |
I/I |
30,059 |
16,093,671 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-29 |
4 |
B |
$13.58 |
$260,727 |
I/I |
19,201 |
16,112,872 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-07-30 |
4 |
B |
$13.91 |
$123,195 |
I/I |
8,855 |
16,121,727 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-08-01 |
4 |
B |
$13.98 |
$36,346 |
I/I |
2,600 |
16,124,327 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-08-02 |
4 |
B |
$13.97 |
$24,898 |
I/I |
1,782 |
16,126,109 |
2.17 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-08-05 |
4 |
B |
$13.98 |
$81,400 |
I/I |
5,824 |
16,131,933 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-08-06 |
4 |
B |
$13.96 |
$4,328 |
I/I |
310 |
16,132,243 |
2.17 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-08-07 |
4 |
B |
$14.00 |
$3,143,000 |
I/I |
224,500 |
16,356,743 |
2.25 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-08-08 |
4 |
B |
$13.98 |
$168 |
I/I |
12 |
16,356,755 |
2.17 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-08-09 |
4 |
B |
$13.99 |
$2,126 |
I/I |
152 |
16,356,907 |
2.17 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2019-10-09 |
4 |
B |
$10.26 |
$181,848 |
I/I |
17,724 |
16,374,631 |
1.5 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2019-10-10 |
4 |
B |
$10.50 |
$186,102 |
I/I |
17,724 |
16,392,355 |
1.5 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
|
2019-10-11 |
4 |
B |
$10.57 |
$187,343 |
I/I |
17,724 |
16,410,079 |
1.5 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2019-10-14 |
4 |
B |
$10.36 |
$361,564 |
I/I |
34,900 |
16,444,979 |
2.25 |
- |
|
145 Records found
|
|
Page 2 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|